Best 3 Blue Chip Stocks to Buy After a Market Pullback -- Including Microsoft (MSFT) Stock

The article highlights three blue-chip stocks—Microsoft, Becton Dickinson, and Clorox—as attractively valued long-term ideas, emphasizing dividends, buybacks, and defensive business models. Microsoft is noted as trading at a forward P/E of 22 with a 0.9% dividend yield, BD at 11.7x forward earnings with a 2.8% yield and 50+ years of dividend growth, and Clorox at 13x forward earnings with a 5.1% yield. Overall, this is a valuation-and-income-focused stock-picking piece with limited immediate market impact.

Analysis

The setup is less about “cheap defensives” and more about a dispersion trade inside quality: MSFT is being derated on capex skepticism, while BDX and CLX are being valued as low-beta cash-return vehicles. That creates a second-order opportunity because all three names are effectively competing for the same capital basket from income-oriented allocators, but only MSFT has a realistic path to re-rate on multiple expansion if AI monetization inflects faster than spending growth.

The market is likely underestimating the duration of the capex digestion phase for large software/platform names. If hyperscaler/AI spend remains elevated for another 2-3 quarters without visible incremental revenue, MSFT can stay range-bound despite fundamental quality; however, that also sets up a sharp upside reaction on even modest evidence of operating leverage. By contrast, BDX’s recurring demand plus buybacks makes it the cleaner downside-defensive compounder if growth fears reaccelerate, and it should attract incremental flows if rates stay sticky and investors keep preferring visible cash yield.

CLX is the most contrarian setup because the valuation looks attractive only if margin repair is faster than input-cost inflation. The risk is that consumer-staples “brand resilience” is masking private-label share pressure that shows up with a lag; if households trade down further, CLX’s volume may hold while mix and pricing erode, capping the rerating. In that scenario, the dividend supports the stock in the near term, but the real catalyst is a credible cost-reset over the next 2-4 quarters, not a macro rebound.

The broader miss is that these are not three equivalent value ideas: MSFT is a quality growth re-entry, BDX is a balance-sheet-and-yield compounder, and CLX is an operating turnaround with income support. That means the best risk/reward is not equal-weighting them, but separating the names by catalyst speed and assigning capital based on how quickly each can surprise relative to expectations.

Key Decisions for Investors

• Long MSFT on a 3-6 month horizon via staged entry on weakness; target a rerating from low-20s P/E toward mid-20s if AI spend converts to visible revenue, with downside contained by balance-sheet quality and dividend support.
• Prefer BDX as the defensive long versus broader healthcare and consumer-staples exposure; buy for 6-12 months with a thesis of low-double-digit total return from earnings stability plus shareholder yield, especially if macro volatility rises.
• Treat CLX as a turnaround/income trade rather than a core compounder; initiate only if you want 12+ month carry, and size smaller because the risk/reward hinges on cost-out execution rather than demand acceleration.
• Pair trade: long MSFT / short a higher-multiple AI-enabler or capex-sensitive tech basket for 1-2 quarters if the market continues to punish spending without monetization; this isolates quality cash flow versus narrative risk.
• If seeking a defensive basket, overweight BDX over CLX until there is proof that CLX margin repair is translating into operating leverage; BDX has the cleaner path to multiple support and lower execution risk.